Related Information




Covington Advises Credit Suisse on $1.6B WuXi PharmaTech Deal


NEW YORK, April 26, 2010 — Charles River Laboratories International, Inc., a global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech (Cayman) Inc., a drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced the signing of a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion. Covington & Burling LLP advised Credit Suisse, financial advisor to WuXi, on the deal.

Credit Suisse, headquartered in Zurich, is a financial services company that operates in more than 50 countries worldwide.

The New York-based Covington corporate team was led by partner Jack S. Bodner, with associate Mary J. Grendell.

Print this page

Covington Advises Credit Suisse on $1.6B WuXi PharmaTech Deal